drugset / Trial / NCT01522547
Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to determine the maximum tolerated dose, safety and effect on induction of fetal hemoglobin of pomalidomide in patients with Sickle Cell Disease.
Timeline
- Start
- 2007-08-01
- Primary completion
- 2012-10-01
- Completion
- 2013-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pomalidomide | Other / unclassified | 0.5 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 1 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 2 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 3 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 4 mg | Oral |